½ÃÀ庸°í¼­
»óǰÄÚµå
1575783

¼¼°èÀÇ IIÇü Äݶó°Õ ½ÃÀå(2024-2031³â)

Global Type II Collagen Market - 2024-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: DataM Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 202 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

º¸°í¼­ °³¿ä

IIÇü Äݶó°Õ ¼¼°è ½ÃÀåÀº 2023³â 2¾ï 1,448¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2031³â¿¡´Â 3¾ï 292¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2031³â ¿¹Ãø ±â°£ µ¿¾È 4.41%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü ¼¼°èÀûÀ¸·Î °í·ÉÈ­ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó °üÀý °Ç°­ ¹× À̵¿¼º ¹®Á¦¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¿¬°ñ°ú °üÀý ±â´ÉÀ» Áö¿øÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁø IIÇü Äݶó°Õ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ¼¼°è IIÇü Äݶó°Õ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖÀ¸¸ç, ƯÈ÷ °üÀý °Ç°­À» ¿ì¼±½ÃÇÏ´Â ³ë³âÃþ°ú Ȱµ¿ÀûÀÎ ¶óÀÌÇÁ½ºÅ¸ÀÏÀ» °¡Áø ¼ÒºñÀÚµé »çÀÌ¿¡¼­ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é, 2050³â±îÁö ³ëÀÎ Àα¸ÀÇ 80%°¡ ÁßÀú¼Òµæ ±¹°¡¿¡ °ÅÁÖÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, °í·ÉÈ­ ¼Óµµ´Â ±× ¾î´À ¶§º¸´Ù »¡¶óÁú °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

2020³â¿¡´Â óÀ½À¸·Î 60¼¼ ÀÌ»ó Àα¸°¡ 5¼¼ ¹Ì¸¸ ¾î¸°À̺¸´Ù ¸¹¾ÆÁú °ÍÀÔ´Ï´Ù. ¶ÇÇÑ 2015³âºÎÅÍ 2050³â±îÁö ¼¼°è Àα¸¿¡¼­ 60¼¼ ÀÌ»ó Àα¸°¡ Â÷ÁöÇÏ´Â ºñÀ²Àº 12%¿¡¼­ 22%·Î °ÅÀÇ µÎ ¹è·Î Áõ°¡ÇÒ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àα¸Åë°èÇÐÀû º¯È­·Î ÀÎÇØ ÀÇ·á ¹× »çȸ Áö¿ø ½Ã½ºÅÛÀ» ³ëÀÎÀÇ ¿ä±¸¿¡ ¸Â°Ô Á¶Á¤Çϱâ À§ÇÑ ±ä±ÞÇÑ Á¶Ä¡°¡ ÇÊ¿äÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ

°ñ°üÀý¿°ÀÇ À¯º´·ü Áõ°¡

°ñ°üÀý¿°ÀÌ Æ¯È÷ ³ë³âÃþ¿¡¼­ ÈçÇØÁö¸é¼­ È¿°úÀûÀÎ Ä¡·á¹ý°ú °üÀý °Ç°­º¸Á¶Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, °üÀý °Ç°­À» Áö¿øÇÏ°í ¿°ÁõÀ» ¾ïÁ¦ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁø IIÇü Äݶó°ÕÀº ÀÌ ÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷µéÀÇ Áõ°¡ÇÏ´Â ¼ö¿ä¿¡ ´ëÀÀÇϱâ À§ÇØ ÀÌ¿¡ µû¶ó °Ç°­±â´É½Äǰ, ±â´É¼º ½Äǰ, ÀǾàǰ¿¡ ´ëÇÑ ¹èÇÕÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, °ñ°üÀý¿°(OA) ¾×¼Ç ¾ó¶óÀ̾𽺿¡ µû¸£¸é, OA À¯º´·üÀº ¿¬·É, ¼ºº°, ÀÎÁ¾¿¡ µû¶ó Â÷À̰¡ ÀÖ½À´Ï´Ù. ¿¬·Éº°·Î´Â OA ȯÀÚÀÇ 43%°¡ 65¼¼ ÀÌ»ó, 88%°¡ 45¼¼ ÀÌ»óÀÔ´Ï´Ù. ¹«¸­ °ñ°üÀý¿°ÀÇ ¿¬°£ ¹ßº´·üÀº 55-64¼¼¿¡¼­ °¡Àå ³ôÁö¸¸, Áõ»óÀÌ ÀÖ´Â ¹«¸­ °ñ°üÀý¿° ȯÀÚÀÇ Àý¹Ý ÀÌ»óÀº 65¼¼ ¹Ì¸¸ÀÔ´Ï´Ù. ¼ºº°·Î´Â OA ȯÀÚÀÇ 62%°¡ ¿©¼ºÀ̸ç, OA´Â 45¼¼ ÀÌÇÏ ³²¼º¿¡¼­ °¡Àå ¸¹ÀÌ ¹ß»ýÇÏÁö¸¸, ±× ÀÌÈĺÎÅÍ´Â ¿©¼º¿¡°Ô ´õ ¸¹ÀÌ ¹ß»ýÇÕ´Ï´Ù. ÀÎÁ¾º°·Î´Â OA ȯÀÚÀÇ 78%°¡ ºñÈ÷½ºÆÐ´Ð°è ¹éÀÎÀÔ´Ï´Ù.

½ºÆ÷Ã÷ ¿µ¾ç¿¡ ´ëÇÑ °ü½ÉÀÇ Áõ°¡

½ºÆ÷Ã÷ ¿µ¾ç¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¼¼°è IIÇü Äݶó°Õ ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿îµ¿¼±¼ö¿Í ÇÇÆ®´Ï½º ¾ÖÈ£°¡µéÀÌ °üÀý °Ç°­, ȸº¹ ¹× ¼º´É Çâ»ó¿¡ Á¡Á¡ ´õ ¸¹Àº °ü½ÉÀ» ±â¿ïÀ̸鼭 IIÇü Äݶó°ÕÀº °üÀýÀÇ ¿ÏÀü¼ºÀ» Áö¿øÇÏ°í ¿°ÁõÀ» ¾ïÁ¦ÇÏ¸ç ¿¬°ñ ȸº¹À» ÃËÁøÇÏ´Â ÀáÀçÀû ÀÌÁ¡ÀÌ ÁÖ¸ñ¹ÞÀ¸¸ç ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

½ºÆ÷Ã÷ ¿µ¾çÁ¦ ½ÃÀå¿¡¼­´Â Äݶó°ÕÀ» ÁÖ¼ººÐÀ¸·Î ÇÏ´Â º¸ÃæÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ Ãæ°ÝÀÌ ½ÉÇÑ ½ºÆ÷Ã÷¸¦ Áñ±â´Â °³ÀεéÀÇ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ÒºñÀÚµéÀº °üÀý °Ç°­ À¯Áö¿Í ºÎ»ó ¿¹¹æ¿¡ µµ¿òÀÌ µÇ´Â Á¦Ç°À» ã°í ÀÖÀ¸¸ç, ÀÌ´Â Àüü ½ºÆ÷Ã÷ ¿µ¾ç ½ÃÀå¿¡¼­ IIÇü Äݶó°Õ ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â Äݶó°ÕÀÌ ¿îµ¿ ´É·Â°ú À¯¿¬¼ºÀ» Çâ»ó½ÃŰ´Â ¿ªÇÒÀ» ÇÑ´Ù´Â ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ½ºÆ÷Ã÷ º¸ÃæÁ¦ ¹× ±â´É¼º ½Äǰ ½ÃÀå¿¡¼­ Áß¿äÇÑ ¼ººÐÀ¸·Î ÀÚ¸® ÀâÀ¸¸é¼­ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

Bulk CEO¿¡ µû¸£¸é, ±Ù·Â ¿îµ¿ÀÇ ÀαⰡ ³ô¾ÆÁö¸é¼­ ÀÌ ¼ÒºñÀÚ Á÷Á¢ ÆÇ¸Å(DTC) ¿µ¾ç ºê·£µå°¡ ±â·ÏÀûÀÎ ¼º°ú¸¦ °ÅµÎ¸ç 2023³â ¸ÅÃâÀÌ 30% Áõ°¡ÇÑ 1¾ï 2,310¸¸ À¯·Î·Î ±ÞÁõÇß´Ù°í ¹àÇû½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀº °­·ÂÇÑ °í°´ À¯Áö¿Í ±â·ÏÀûÀÎ ½Å±Ô °í°´ È®º¸·Î, Áö³­ÇØ Bulk´Â ¾à 80¸¸ ¸íÀÇ ½Å±Ô °í°´À» È®º¸ÇØ 900¸¸ °³ ÀÌ»óÀÇ Á¦Ç°À» ÆÇ¸ÅÇß½À´Ï´Ù. Ŭ¸®¾î À¯Ã» ´Ü¹éÁúÀÌ °¡Àå ºü¸£°Ô ¼ºÀåÇÑ Á¦Ç°±ºÀ¸·Î ºÎ»óÇßÀ¸¸ç, »ýȰºñ À§±â ¼Ó¿¡¼­ ¹ë·ù ¿¡¼¾½º ½Ã¸®Áî°¡ È£Á¶¸¦ º¸¿´½À´Ï´Ù.

Å©·¹¾ÆÆ¾ Á¦Ç°Àº ±ÙÀ° °­È­¿¡ ÁßÁ¡À» µÐ °í°´µé »çÀÌ¿¡¼­ °è¼Ó Àα⸦ ¾ò¾úÀ¸¸ç, Äݶó°Õ°ú ¸¶±×³×½· Á¦Ç°Àº ȸº¹ ¼Ö·ç¼ÇÀ¸·Î ¼ö¿ä°¡ Áõ°¡ÇßÀ¸¸ç, BulkÀÇ ³î¶ó¿î ¸ÅÃâÀº Á¶Á¤ EBITDA¸¦ 2022³â 260 ¸¸ À¯·Î¿¡¼­ 930 ¸¸ À¯·Î·Î ²ø¾î ¿Ã·ÈÀ¸¸ç ¼¼Àü ÀÌÀÍÀº ¼¼Àü ÀÌÀÍÀº ÀÎÇ÷¹À̼ÇÀ¸·Î ÀÎÇÑ ¿øÀÚÀç ºñ¿ë »ó½Â¿¡µµ ºÒ±¸Çϰí Àü³âµµÀÇ 6¸¸ 6,000À¯·Î¿¡¼­ 6¹é¸¸ À¯·Î·Î Áõ°¡Çß½À´Ï´Ù.

ºñ°Ç°ú À±¸®Àû °ü½É»ç

¼ÒºñÀÚ ¼ö¿ä°¡ ½Ä¹°¼º ¹× ¹«³ó¾à Á¦Ç°À¸·Î À̵¿ÇÔ¿¡ µû¶ó ÀϺΠ½ÃÀå¿¡¼­´Â ÀϹÝÀûÀ¸·Î ´ß Èä°ñ ¹× ±âŸ µ¿¹° Á¶Á÷À» ¿ø·á·Î ÇÏ´Â IIÇü Äݶó°Õ°ú °°Àº µ¿¹°¼º Á¦Ç°¿¡ ´ëÇÑ °æ°è½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À±¸®Àû ŵµ´Â Àü ¼¼°èÀûÀ¸·Î ä½ÄÁÖÀÇÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó IIÇü Äݶó°Õ ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, IIÇü Äݶó°Õ ½ÃÀåÀº °¢ ºê·£µå°¡ µ¿¹° º¹Áö¿Í Áö¼Ó°¡´É¼ºÀ» µÑ·¯½Ñ À±¸®Àû ³í¶õÀ» ±Øº¹ÇÏ´Â °úÁ¤¿¡¼­ µµÀü¿¡ Á÷¸éÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. µ¿¹°¼º Äݶó°ÕÀÇ »ý»ê ¹æ½ÄÀÌ È¯°æ¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ºñÆÇÀ» ¹Þ´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ Áö¼Ó°¡´É¼º°ú À±¸®Àû Á¶´ÞÀÌ ÃÖ¿ì¼± ¼øÀ§ÀÎ ½ÃÀå¿¡¼­´Â ¼ö¿ä°¡ ´õ¿í °¨¼ÒÇÏ°í ½ÃÀå ¼ºÀåÀÌ ¾ïÁ¦µÉ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¼¼°è IIÇü Äݶó°Õ ½ÃÀåÀº ÇüÅÂ, °ø±Þ¿ø, ¿ëµµ, Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

IIÇü Äݶó°Õ ÇǺΠ°Ç°­ Á¦Ç°¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ö¿ä Áõ°¡

È­Àåǰ ºÎ¹®Àº ÇǺΠ°Ç°­ Á¦Ç°¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ö¿ä Áõ°¡¿Í ÇǺΠź·Â, º¸½À ¹× Àü¹ÝÀûÀÎ ¿Ü¸ð¸¦ °³¼±ÇÏ´Â Äݶó°ÕÀÇ ¿ªÇÒ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¼¼°è IIÇü Äݶó°Õ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¼ÒºñÀÚµéÀÌ Àþ¾î º¸ÀÌ´Â ¿Ü¸ð¸¦ À¯ÁöÇÏ´Â µ¥ ÁßÁ¡À» µÎ¸é¼­ IIÇü Äݶó°ÕÀ» ÁÖ¼ººÐÀ¸·Î ÇÏ´Â ¾ÈƼ¿¡ÀÌ¡ Á¦Ç°ÀÇ ÀαⰡ ±Þ»ó½ÂÇϰí ÀÖ½À´Ï´Ù.

³ëÈ­ ¹æÁö¿Í ÇǺΠȸÃá¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 IIÇü Äݶó°ÕÀÇ ÀÔÁõµÈ È¿°ú·Î ÀÎÇØ È­Àåǰ ½ÃÀåÀÌ ¹ßÀüÇϰí ÀÖ½À´Ï´Ù. È­Àåǰ ¾÷°è´Â Äݶó°ÕÀÌ ÇÔÀ¯µÈ ¸¶½ºÅ©, ·Î¼Ç, ¼·Ãë °¡´ÉÇÑ ¹Ì¿ë º¸Á¶Á¦ µî Çõ½ÅÀûÀÎ Á¦Ç° ÇüÅ·Π²÷ÀÓ¾øÀÌ ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 1¿ù 24ÀÏ °ÖÅ丣´Â ¹ßÈ¿¸¦ ÅëÇØ »ý»êµÈ ºñ°Ç Äݶó°ÕÀÎ NuCollÀ» Ãâ½ÃÇϸç Çì¾îÄÉ¾î ½ÃÀå¿¡ ÁøÃâÇß½À´Ï´Ù.

½ÃÀåÀÇ Áö¸®Àû Á¡À¯À²

ºÏ¹ÌÀÇ °üÀý Àå¾Ö À¯º´·ü Áõ°¡

ºÏ¹Ì°¡ ¼¼°è IIÇü Äݶó°Õ ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº Àα¸ °í·ÉÈ­°¡ ºü¸£°Ô ÁøÇàµÇ°í ÀÖÀ¸¸ç, °ñ°üÀý¿°°ú °°Àº °üÀý ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó °üÀý °Ç°­º¸Á¶Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, ¿¬°ñÀ» ÁöÁöÇÏ°í °üÀý ±â´ÉÀ» °³¼±ÇÒ ¼ö ÀÖ´Ù´Â ÀÌÀ¯·Î IIÇü Äݶó°ÕÀÌ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

Äݶó°Õ º¸ÃæÁ¦ÀÇ È¿´É¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ±¤¹üÀ§ÇÑ ¸¶ÄÉÆÃ ³ë·Â°ú °­·ÂÇÑ À¯Åë ä³Î¿¡ ÈûÀÔ¾î ºÏ¹Ì ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ¶ÇÇÑ °íµµ·Î ¹ß´ÞÇÑ ÇコÄɾî ÀÎÇÁ¶ó¿Í źźÇÑ °Ç°­±â´É½Äǰ ½ÃÀåÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ¾î Äݶó°Õ ±â¹Ý Á¦Ç°¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ¿ëÀÌÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â Á¦Ç° Çõ½Å°ú »õ·Î¿î Á¦Çü¿¡ ´ëÇÑ ÁýÁß°ú ÇÔ²² ºÏ¹Ì°¡ ¼¼°è IIÇü Äݶó°Õ ½ÃÀå¿¡¼­ ¼±µµÀûÀÎ À§Ä¡¸¦ À¯ÁöÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå °æÀï »óȲ

½ÃÀåÀÇ ÁÖ¿ä ¼¼°è ±â¾÷À¸·Î´Â Ashland Inc., Athos Collagen Private Limited, Chondrex, Inc. REPROCELL Inc., KOKEN CO., LTD., JINBO BIO-PHARMACEUTICAL CORPORATION LIMITED µîÀÌ ÀÖ½À´Ï´Ù.

·¯½Ã¾Æ-¿ìÅ©¶óÀ̳ª ÀüÀï ¿µÇ⠺м®

ÇöÀç ÁøÇà ÁßÀÎ ·¯½Ã¾Æ-¿ìÅ©¶óÀ̳ª ÀüÀïÀº ¼¼°è IIÇü Äݶó°Õ ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, °ø±Þ¸Á°ú ¼ÒºñÀÚ Çൿ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ºÐÀïÀº µ¿À¯·´ÀÇ ³ó¾÷ Ȱµ¿°ú ¹«¿ª °æ·Î¸¦ ¹æÇØÇÏ¿© ÀÌ Áö¿ª¿¡¼­ Á¶´ÞÇÏ´Â ÁÖ¿ä ¿ø·áÀÇ ºÎÁ·°ú °¡°Ý »ó½ÂÀ» ÃÊ·¡Çß½À´Ï´Ù. ÀÌ·¯ÇÑ °ø±Þ¸Á È¥¶õÀº IIÇü Äݶó°Õ ½ÃÀå Á¦Á¶¾÷üÀÇ »ý»ê ºñ¿ë »ó½ÂÀ¸·Î À̾îÁ³°í, ÀϺΠ¾÷ü´Â ÀÌ·¯ÇÑ ºñ¿ëÀ» ¼ÒºñÀÚ¿¡°Ô Àü°¡ÇÒ ¼ö¹Û¿¡ ¾ø¾ú½À´Ï´Ù.

ÀüÀïÀº ±¤¹üÀ§ÇÑ °æÁ¦ ºÒ¾ÈÁ¤À¸·Î À̾îÁ® ¼ÒºñÀÚÀÇ ¼Òºñ ÆÐÅϰú ¿ì¼±¼øÀ§¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ºÒÈ®½ÇÇÑ ½Ã±â¿¡ ¼ÒºñÀÚµéÀº IIÇü Äݶó°Õ Á¦Ç°À» Æ÷ÇÔÇÑ º¸ÃæÁ¦¿¡ ´ëÇÑ Àç·®Àû ÁöÃâÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ¼ö¿ä°¡ º¯µ¿ÇÏ°í ½ÃÀå ¼ºÀåÀÌ µÐÈ­µÉ ¼ö ÀÖÀ¸¸ç, ƯÈ÷ ¿µÇâÀ» ¹Þ´Â ±¹°¡·ÎºÎÅÍÀÇ ¼öÀÔ¿¡ Å©°Ô ÀÇÁ¸ÇÏ´Â Áö¿ª¿¡¼­´Â ½ÃÀå ¼ºÀåÀÌ µÐÈ­µÉ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä ¹ßÀü

2023³â 11¿ù 4ÀÏ, ÇÏÀ̵¥¶ó¹Ùµå¿¡ º»»ç¸¦ µÐ Á¦¾àȸ»ç ¸®ÆÄ¸¶(Lee Pharma)´Â ¾Æ¶ø¿¡¹Ì¸®Æ®¿¡¼­ Bio-Cartilage SmoothWalk Á¤Á¦ÀÇ ÆÇ¸Å Çã°¡¸¦ ȹµæÇß½À´Ï´Ù. Àεµ»ê °Ç°­±â´É½ÄǰÀ¸·Î, ÀÌ ¸¶ÀϽºÅæÀº ȸ»ç¿¡ ÀÖ¾î Áß¿äÇÑ ÀÌÁ¤Ç¥°¡ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

2022³â 3¿ù 3ÀÏ, Áß±¹ÀÇ ÁÖ¿ä ºñŸ¹Î ¹× ¿µ¾ç º¸ÃæÁ¦ ±â¾÷ÀÎ ByHealth´Â ÀÚ»çÀÇ °üÀý °Ç°­ ºê·£µåÀÎ HighflexÀÇ ½ÅÁ¦Ç°ÀÎ Äݶó°Õ Á¦Ç°À» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Á¦Ç°Àº Bioiberica(¹Ù¸£¼¿·Î³ª)ÀÇ ³×ÀÌÆ¼ºê(¹Ìº¯¼º) IIÇü Äݶó°Õ ¼ººÐÀÎ Collavant n2¸¦ ÇÔÀ¯Çϰí ÀÖÀ¸¸ç, ÀÓ»óÀûÀ¸·Î ¹«¸­ÀÇ ºÒÆíÇÔÀ» ¿ÏÈ­ÇÏ°í °üÀý ±â´ÉÀ» °³¼±ÇÏ´Â °ÍÀ¸·Î ÀÔÁõµÈ ¹Ù ÀÖ½À´Ï´Ù.

2021³â 4¿ù 20ÀÏ, Lonza´Â UC-II ¹Ìº¯¼º Äݶó°Õ ¿ø·á ¶óÀξ÷À» È®ÀåÇÏ¿© Non-GMO ÇÁ·ÎÁ§Æ®¿¡¼­ °ËÁõÇÑ À¯±â³ó ÀÎÁõ Äݶó°ÕÀ» »ç¿ëÇÑ »õ·Î¿î º¸ÃæÁ¦¸¦ Ãâ½ÃÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. »õ·Î¿î UC-II ¹Ìº¯¼º IIÇü Äݶó°ÕÀº ¼ÒºñÀÚ Ä£È­ÀûÀÎ 1ÀÏ 1ȸ º¹¿ë·®À» Á¦°øÇÔÀ¸·Î½á ÀÌ ¹®Á¦¸¦ ÇØ°áÇϰí, À¯±â³ó °üÀý °Ç°­ ½ÃÀåÀÇ »ç¶÷µé¿¡°Ô º¸´Ù Æí¸®ÇÑ ¼±ÅñÇÀ» Á¦°øÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

º¸°í¼­¸¦ ±¸¸ÅÇØ¾ß ÇÏ´Â ÀÌÀ¯

ÇüÅÂ, °ø±Þ¿ø, ¿ëµµ, Áö¿ªº°·Î ¼¼°è IIÇü Äݶó°Õ ½ÃÀåÀÇ ¼¼ºÐÈ­¸¦ ½Ã°¢È­Çϰí ÁÖ¿ä »ó¾÷Àû ÀÚ»ê°ú Ç÷¹À̾ ÀÌÇØÇÕ´Ï´Ù.

Æ®·»µå ¹× °øµ¿°³¹ß ºÐ¼®À» ÅëÇÑ »ç¾÷±âȸ ¹ß±¼À» ÁøÇàÇÕ´Ï´Ù.

¸ðµç ¼öÁØÀÇ ¼¼ºÐÈ­¸¦ Æ÷°ýÇÏ´Â IIÇü Äݶó°Õ ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ µ¥ÀÌÅÍ ¼¼Æ®¸¦ Æ÷ÇÔÇÏ´Â ¿¢¼¿ ½ºÇÁ·¹µå½ÃÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

PDF º¸°í¼­´Â öÀúÇÑ Á¤¼ºÀû ÀÎÅͺä¿Í ¸é¹ÐÇÑ Á¶»ç ÈÄ Á¾ÇÕÀûÀÎ ºÐ¼®À¸·Î ±¸¼ºµË´Ï´Ù.

ÁÖ¿ä ±â¾÷ÀÇ ÁÖ¿ä Á¦Ç°À» Æ÷ÇÔÇÑ Á¦Ç° ¸ÊÇÎ(¿¢¼¿ ¹öÀü)À» Á¦°øÇÕ´Ï´Ù.

¼¼°è IIÇü Äݶó°Õ ½ÃÀå º¸°í¼­´Â ¾à 62 °³ÀÇ Ç¥, 53 °³ÀÇ ±×¸², 202 ÆäÀÌÁö¸¦ Á¦°øÇÕ´Ï´Ù.

´ë»ó µ¶ÀÚ

Á¦Á¶¾÷ü/±¸¸ÅÀÚ

¾÷°è ÅõÀÚÀÚ/ÅõÀÚÀºÇà°¡

Á¶»ç Àü¹®°¡

½ºÅ¸Æ®¾÷

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå Á¤ÀÇ¿Í °³¿ä

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • °ñ°üÀý¿° À¯º´·ü »ó½Â
      • ½ºÆ÷Ã÷ ¿µ¾ç¿¡ ´ëÇÑ °ü½É »ó½Â
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
      • ºñ°Ç°ú À±¸®Àû ¿ì·Á
    • ±âȸ
    • ¿µÇ⠺м®

Á¦5Àå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ºÐ¼®
  • °ø±Þ¸Á ºÐ¼®
  • °¡°Ý ºÐ¼®
  • ±ÔÁ¦ ºÐ¼®
  • ·¯½Ã¾Æ¡¤¿ìÅ©¶óÀ̳ª ÀüÀï ¿µÇ⠺м®
  • DMIÀÇ °ßÇØ

Á¦6Àå Çüź°

  • °ÇÁ¶
  • ¾×ü

Á¦7Àå °ø±Þ¿øº°

  • ¼Ò
  • µÅÁö
  • °¡±Ý
  • ±âŸ

Á¦8Àå ¿ëµµº°

  • ½Äǰ ¹× À½·á
  • ÇコÄɾî
  • È­Àåǰ
  • ±âŸ

Á¦9Àå Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ³²¹Ì
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï »óȲ

  • °æÀï ½Ã³ª¸®¿À
  • ½ÃÀå »óȲ/Á¡À¯À² ºÐ¼®
  • M&A ºÐ¼®

Á¦11Àå ±â¾÷ °³¿ä

  • Ashland Inc.
    • ±â¾÷ °³¿ä
    • Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í ¼³¸í
    • À繫 °³¿ä
    • ÁÖ¿ä ¹ßÀü
  • Athos Collagen Private Limited
  • Chondrex, Inc.
  • Advanced BioMatrix
  • Rousselot
  • Takara Bio Inc.
  • SouthernBiotech
  • REPROCELL Inc.
  • KOKEN CO., LTD.
  • JINBO BIO-PHARMACEUTICAL CORPORATION LIMITED(*LIST NOT EXHAUSTIVE)

Á¦12Àå ºÎ·Ï

ksm 24.11.19

Report Overview

The Global Type II Collagen Market reached US$ 214.48 million in 2023 and is expected to reach US$ 302.92 million by 2031, growing at a CAGR of 4.41% during the forecast period 2024-2031.

As the aging population grows globally, there is an increasing awareness of joint health and mobility issues. Type II collagen, known for its ability to support cartilage and joint function, is seeing heightened demand. The trend drives global type II collagen market expansion, particularly among elderly consumers and individuals with active lifestyles who prioritize joint health.

According to the World Health Organization, countries face significant challenges in preparing their health and social systems for the rapid demographic shift toward an aging population. By 2050, it is projected that 80% of older adults will reside in low- and middle-income countries and the pace of population aging is accelerating at an unprecedented rate.

In 2020, for the first time, the number of people aged 60 years and older surpassed the number of children under the age of five. Furthermore, between 2015 and 2050, the proportion of the global population over 60 will nearly double, increasing from 12% to 22%. This demographic change requires urgent action to adapt healthcare and social support systems to the needs of older individuals.

Market Dynamics

Rising Prevalence of Osteoarthritis

As osteoarthritis becomes more common, especially among the aging population, the demand for effective treatments and joint health supplements significantly increases. Type II collagen, known for its role in supporting joint health and reducing inflammation, is increasingly being incorporated into dietary supplements, functional foods and pharmaceuticals to address the growing needs of those affected by this condition.

For instance, according to the Osteoarthritis (OA) Action Alliance, the prevalence of OA varies by age, gender and ethnicity. Age-wise, 43% of individuals with OA are 65 or older and 88% are 45 or older. The highest annual incidence of knee OA occurs between the ages of 55 and 64, although more than half of those with symptomatic knee OA are under 65. Gender differences show that 62% of individuals with OA are women. While OA is more common in men under 45, it becomes more prevalent in women after that age. In terms of ethnicity, 78% of those with OA are non-Hispanic whites.

Growing Interest in Sports Nutrition

The growing interest in sports nutrition is expected to drive the global type II collagen market significantly. As athletes and fitness enthusiasts increasingly focus on joint health, recovery and performance enhancement, type II collagen is gaining attention for its potential benefits in supporting joint integrity, reducing inflammation and promoting cartilage repair, driving the market growth.

The market is witnessing a rise in demand for collagen-based supplements, especially from individuals engaged in high-impact sports. These consumers seek products that can help maintain their joint health and prevent injury, contributing to the expansion of the type II collagen segment within the broader sports nutrition market. This trend is further supported by the growing awareness of collagen's role in improving mobility and flexibility, making it a key ingredient in the market for sports supplements and functional foods.

According to Bulk CEO, the rising popularity of strength training has propelled the direct-to-consumer (DTC) nutrition brand to a record-breaking performance, with revenues surging by 30% to EUR 123.1 million in 2023. Strong customer retention and record-high new customer acquisition were key drivers behind this growth. Bulk added nearly 800,000 new customers last year and sold over nine million products, with clear whey protein emerging as the fastest-growing line and the value essentials range performing well amid the cost of living crisis.

Creatine products remained popular among customers focused on muscle mass building, while collagen and magnesium products saw increased demand as recovery solutions. Bulk's impressive revenues boosted adjusted EBITDA to EUR 9.3 million, up from EUR 2.6 million in 2022 and pre-tax profits rose to EUR 6 million, compared to just EUR 66k the previous year, despite inflation-driven ingredient cost hikes.

Vegan and Ethical Concerns

As consumer demand shifts towards plant-based and cruelty-free products, a growing segment of the market is becoming increasingly wary of products derived from animal sources, such as type II collagen, which is typically sourced from chicken sternum or other animal tissues. This ethical stance, combined with the rising vegan population globally, may hinder the growth of the type II collagen market, as consumers seek alternative, plant-based solutions for joint health and skin care.

Moreover, the type II collagen market is also likely to face challenges as brands navigate the ethical debates around animal welfare and sustainability. The production methods for animal-derived collagen are often scrutinized for their environmental impact, which can further dampen demand in markets where sustainability and ethical sourcing are high priorities, restraining market growth.

Market Segment Analysis

The global type II collagen market is segmented based on form, source, application and region.

Rising Consumer Demand for Type II Collagen Skin Health Products

The cosmetics segment holds the largest share of the global type II collagen market due to a combination of rising consumer demand for skin health products and the increasing awareness of collagen's role in enhancing skin elasticity, hydration and overall appearance. As consumers become more focused on maintaining a youthful appearance, there is a surge in the popularity of anti-aging products, with type II collagen becoming a key ingredient.

The growing demand for anti-aging and skin-rejuvenating solutions is driving the cosmetics market forward with type II collagen's proven benefits. The cosmetics industry is continually evolving with innovative product formats such as collagen-infused masks, lotions and ingestible beauty supplements. For instance, on January 24, 2023, Geltor expanded into the hair care market with the launch of NuColl, a vegan collagen produced through fermentation.

Market Geographical Share

Increasing Prevalence of Joint Disorders in North America

North America is expected to dominate the global type II collagen market. The primary driver is the region's rapidly aging population, which is leading to an increasing prevalence of joint disorders such as osteoarthritis. This is creating significant demand for joint health supplements, where type II collagen is widely used for its potential to support cartilage and improve joint function.

Growing consumer awareness about the benefits of collagen supplements, driven by extensive marketing efforts and strong distribution channels, is contributing to market expansion in North America. The region also benefits from a highly developed healthcare infrastructure and a robust dietary supplement market, allowing for easier access to collagen-based products. These trends, along with a focus on product innovation and new formulations, are helping North America maintain its leading position in the global type II collagen market.

Market Competitive Landscape

The major global players in the market include Ashland Inc., Athos Collagen Private Limited, Chondrex, Inc., Advanced BioMatrix, Rousselot, Takara Bio Inc., SouthernBiotech, REPROCELL Inc., KOKEN CO., LTD. and JINBO BIO-PHARMACEUTICAL CORPORATION LIMITED.

Russia-Ukraine War Impact Analysis

The ongoing Russia-Ukraine war has significantly affected the global type II collagen market, influencing supply chains and consumer behavior. The conflict has disrupted agricultural activities and trade routes in Eastern Europe, leading to shortages and increased prices of key ingredients sourced from the region. This disruption in supply chains has resulted in heightened production costs for manufacturers in the type II collagen market, prompting some companies to pass these costs on to consumers.

The war has contributed to broader economic instability, affecting consumer spending patterns and priorities. In times of uncertainty, consumers may reduce discretionary spending on supplements, including type II collagen products. This could slow market growth as demand fluctuates, especially in regions heavily reliant on imports from affected countries.

By Form

Dry

Liquid

By Source

Bovine

Porcine

Poultry

Others

By Application

Food and beverage

Healthcare

Cosmetics

Others

By Region

North America

US

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

Middle East and Africa

Key Developments

On November 4, 2023, Lee Pharma, a Hyderabad-based pharmaceutical company, received marketing authorization to launch its Bio-Cartilage SmoothWalk tablets in the United Arab Emirates. This milestone marks a significant achievement for the company, as Bio-Cartilage SmoothWalk becomes the first Indian nutraceutical product to be licensed in the UAE.

On March 3, 2022, ByHealth, a leading vitamin and dietary supplements company in China, introduced a new collagen product under its Highflex joint health brand. This product features Collavant n2, a native (undenatured) type II collagen ingredient from Bioiberica (Barcelona), which has been clinically proven to alleviate knee discomfort and improve joint function.

On April 20, 2021, Lonza announced the expansion of its UC-II undenatured collagen ingredient line with the launch of a new supplement made from certified organic collagen and verified by the Non-GMO Project. The new UC-II undenatured type II collagen aims to solve this by offering a consumer-friendly, once-daily dose, providing a more convenient option for those in the organic joint-health market.

Why Purchase the Report?

To visualize the global type II collagen market segmentation based on form, source, application and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel spreadsheet containing a comprehensive dataset of the type-ii-collagen-market, covering all levels of segmentation.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global type II collagen market report would provide approximately 62 tables, 53 figures and 202 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Form
  • 3.2. Snippet by Source
  • 3.3. Snippet by Application
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Osteoarthritis
      • 4.1.1.2. Growing Interest in Sports Nutrition
    • 4.1.2. Restraints
      • 4.1.2.1. Vegan and Ethical Concerns
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. By Form

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 6.1.2. Market Attractiveness Index, By Form
  • 6.2. Dry*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Liquid

7. By Source

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 7.1.2. Market Attractiveness Index, By Source
  • 7.2. Bovine*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Porcine
  • 7.4. Poultry
  • 7.5. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Food and beverage*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Healthcare
  • 8.4. Cosmetics
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. US
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. UK
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Form
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Ashland Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Athos Collagen Private Limited
  • 11.3. Chondrex, Inc.
  • 11.4. Advanced BioMatrix
  • 11.5. Rousselot
  • 11.6. Takara Bio Inc.
  • 11.7. SouthernBiotech
  • 11.8. REPROCELL Inc.
  • 11.9. KOKEN CO., LTD.
  • 11.10. JINBO BIO-PHARMACEUTICAL CORPORATION LIMITED (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦